Natco Pharma designates two senior VPs for R&D roles
Natco Pharma designated Gnanadeva Chalapathy Gudipati as Senior Vice President of Analytical Research & Development and Madhava Rao Karicherla as Vice President of Formulation Research & Development, effective July 6, 2026, to strengthen its R&D capabilities.
*this image is generated using AI for illustrative purposes only.
Natco Pharma has designated Gnanadeva Chalapathy Gudipati as Senior Vice President of Analytical Research & Development and Madhava Rao Karicherla as Vice President of Formulation Research & Development, effective July 6, 2026. The appointments aim to strengthen the company's research and development capabilities across its pharmaceutical operations, specifically within the Pharma Division, Kothur Unit.
The designations were made in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the disclosure to the stock exchanges, detailing the profiles and terms of appointment for the new senior management personnel.
Gnanadeva Chalapathy Gudipati brings experience in resolving complex technical problems and managing internal and external audits. He has been associated with Natco Pharma Limited since September 15, 2017, and previously worked with Mylan Laboratories Limited. He holds an Executive Programme in Operations Management from the Indian Institute of Management, Kozhikode, and a Master's degree in Chemistry from the Institute of Chemical Sciences, Indore.
Madhava Rao Karicherla has over 20 years of experience in global generic product development, ANDA filings, and operations management. He joined Natco Pharma Limited on November 15, 2024, and has worked with companies such as Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited, and Ranbaxy Research Laboratories. He holds a Master's of Pharmacy from the National Institute of Pharmaceutical Education and Research, Mohali, and a Bachelor of Pharmacy from Osmania University.
The terms of appointment for both officials are as per the company's policy. The disclosure confirmed that there is no specific relationship between the appointees and the directors of the company that requires disclosure under the regulations.
| Name | Designation | Date of Appointment | Prior Experience |
|---|---|---|---|
| Mr. Gnanadeva Chalapathy Gudipati | Senior Vice President - Analytical Research & Development | July 6, 2026 | Mylan Laboratories Limited |
| Mr. Madhava Rao Karicherla | Vice President – Formulation Research & Development | July 6, 2026 | Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited, Ranbaxy Research Laboratories |
Historical Stock Returns for Natco Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.49% | +3.82% | +10.75% | +5.71% | -2.37% | -9.62% |
How will these new R&D leadership roles influence Natco Pharma's pipeline of complex generic filings over the next two years?
What specific strategic priorities will the Kothur Unit focus on following this strengthening of its analytical and formulation capabilities?
Could these appointments signal an acceleration in Natco's plans for expanding into specialized therapeutic areas?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
